OliX Pharmaceuticals, Inc

226950· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩119,800+13.66%

2026-08-04

Financials

Valuation Metrics

OliX Pharmaceuticals, Inc's Market Cap is ₩2.5T. At end of 2025 it was ₩3.0T. Ranked #167 of 2,436 in KR market (top 7%), #29 of 1,649 on KOSDAQ (top 2%), #19 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 8%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	2.52T KRW	KR#167/2,436 Sec#19/234
Revenue	17.26B KRW	KR#2,171/2,436 Sec#160/234
Net Income	-12.25B KRW	KR—/2,436 Sec—/234
Total Assets	186.35B KRW	KR#1,324/2,436 Sec#100/234
Net Assets	145.39B KRW	KR#1,124/2,436 Sec#82/234
Employees	69	KR#1,867/2,436 Sec#160/234
Value
P/B	17.36x	KR#2,382/2,436 Sec#220/234
P/S	146.17x	KR#2,398/2,436 Sec#217/234
Profitability
ROE	-8.42%	KR#1,866/2,436 Sec#143/234
ROA	-6.57%	KR#1,962/2,436 Sec#150/234
Op. Margin	-188.36%	KR#2,336/2,436 Sec#185/234
Revenue Growth	265.80%	KR#48/2,436 Sec#8/234
Financial Health
Debt Ratio	128.17%	KR#813/2,436 Sec#95/234
Total Debt	20.54B KRW	KR#1,347/2,436 Sec#111/234
Cash	11.06B KRW	KR#1,619/2,436 Sec#124/234
Current Ratio	6.59x	KR#197/2,436 Sec#46/234
Performance
1Y Return	153.54%	KR#74/2,436 Sec#5/234
1M Return	-19.76%	KR#2,183/2,436 Sec#216/234
From 52W High	-44.79%	KR#966/2,436 Sec#77/234
1Y MDD	-56.76%	KR#1,238/2,436 Sec#101/234
Trading
Volume	484,026 shares	KR#284/2,436 Sec#32/234
Foreign Own.	8.54%	KR#536/2,436 Sec#47/234
Per Share
EPS	-577 KRW	KR—/2,436 Sec—/234
BPS	6,493 KRW	KR#1,247/2,436 Sec#88/234

Company Info

CEO 이동기

Employees 69

Founded 2010

HQ 경기도 성남시, KR

Website www.olixpharma.com

동사는 RNA간섭 플랫폼 기반 신약개발 기업으로, 자가전달 비대칭 siRNA 원천기술을 보유하여 아시아 최초로 임상에 진입함. 모든 유전자 표적이 가능하고 후보물질 선정 기간을 1년 이내로 단축할 수 있음. 비대칭 siRNA 구조로 오프타겟 효과 및 면역 반응을 최소화하고 GalNAc-asiRNA 플랫폼으로 간 세포 전달 효율을 높여 글로벌 기술 경쟁력을 확보하고 있음. 올릭스는 2010년에 설립되었으며 경기도 성남시에 본사를 두고 있습니다.